To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period

NCT05324293 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Androgenetic Alopecia

Interventions

DRUG: HMI-115

Sponsor

Hope Medicine (Nanjing) Co., Ltd